Skip to content
Bamboo Works
Search
Register / Sign in
MSCI China | MSCI China Small-Cap | Hang Seng Index | Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

Chongqing Zhifei Biological

CanSino looks for next growth shot in ‘life after Covid’

The vaccine maker is back to square one as a brief windfall fueled by demand for its Covid vaccines rapidly fades Key Takeaways: CanSino logged sizable asset impairments for its…
March 7, 2023
6185.HK 688185.SHG

Riding Covid Vaccine Highs, CanSino Plans Swiss Listing

The first vaccine stock to be listed in the both Mainland China and Hong Kong will issue global depositary receipts (GDRs) in SwitzerlandKey Takeaways:After successful listings in Shanghai and Hong…
January 17, 2023

Clover Biopharma Gets Critical Cash Booster After Covid Vaccine Approval

The innovative drug maker announced a major share sale a day after its self-developed Covid-19 vaccine got the green light for emergency use in ChinaKey Takeaways:Clover Biopharmaceuticals raised $64 million…
December 15, 2022

CanSino’s Covid Vaccine Gets WHO Nod. But Is It Too Little, Too Late?

The company’s Convidecia has received emergency-use authorization from the World Health Organization, becoming the third Chinese vaccine to get that nod Key Takeaways: CanSino’s Covid-19 vaccine Convidecia will be admitted…
May 26, 2022

Recent Articles

March 7, 2023

CanSino looks for next growth shot in ‘life after Covid’

6185.HK 688185.SHG
January 17, 2023

Riding Covid Vaccine Highs, CanSino Plans Swiss Listing

December 15, 2022

Clover Biopharma Gets Critical Cash Booster After Covid Vaccine Approval

May 26, 2022

CanSino’s Covid Vaccine Gets WHO Nod. But Is It Too Little, Too Late?

RELATED ARTICLES

  1. Clover Biopharmaceuticals Ltd. faces a potentially damaging fight
    April 3, 2025
    Dispute over Covid vaccines casts doubt on Clover Bio recovery
    2197.HK
  2. January 20, 2025
    Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
    ZYBT.US
  3. March 25, 2025
    Everest Medicines drives growth with AI-powered mRNA pipeline
    1952.HK
  4. January 16, 2025
    WuXi Biologics sells vaccine plant as new U.S. law looms
    2269.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Audio/Video
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • AI/Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2021 - 2025 Bamboo Works. All rights reserved.